bortezomib and dexamethasone
Showing 1 - 25 of 2,817
Immunoglobulin Light-chain Amyloidosis Trial (Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules
Not yet recruiting
- Immunoglobulin Light-chain Amyloidosis
- Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- (no location specified)
Mar 18, 2023
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))
Recruiting
- Relapsed or Refractory Multiple Myeloma
- SVd (Selinexor+Bortezomib+dexamethasone)
- Vd (Bortezomib+dexamethasone)
-
Hefei, Anhui, China
- +33 more
Aug 14, 2022
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Isatuximab
- +4 more
-
Hamburg, Germany
- +3 more
Dec 16, 2022
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)
Not yet recruiting
- Multiple Myeloma
- +2 more
- Drug and medical device
-
Poitiers, FranceCHU Poitiers
Jun 1, 2023
Daratumumab in Combination With Bortezomib, Thalidomide, and
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
- (no location specified)
Sep 27, 2022
Multiple Myeloma Trial in Rionero in Vulture (Bortezomib, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
-
Rionero in Vulture, Potenza, ItalyIrccs Crob
Mar 24, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Waldenström's Macroglobulinemia Trial in Ulm (Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab,
Active, not recruiting
- Waldenström's Macroglobulinemia
- Dexamethasone, Rituximab, Cyclophosphamide
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
-
Ulm, GermanyUniversity Hospital Ulm
May 26, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Myeloma
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Sep 5, 2022
Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)
Active, not recruiting
- Amyloidosis; Systemic
- Daratumumab
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 9, 2022
Multiple Myeloma Trial in Denmark, Estonia, Norway (Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule)
Recruiting
- Multiple Myeloma
- Selinexor 20 MG Oral Tablet
- +3 more
-
Aalborg, Denmark
- +10 more
Apr 22, 2022
Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome injection
- +2 more
-
Beijing, Beijing, ChinaBeijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023